

Test Ref. FB-5485-83819-6

Lab Ref. B2601290500

Patient Name

Physician Name

**JANE DOE**
**DR LEE**

Patient ID

**B860374826482**

Gender

**Female**

Date of Birth

**1958-05-18**




Blood Sample Date

**2026-02-06**

Test Date

**2026-02-20**

### TEST SCORES


**FIBROSIS**
**0.85**
**F4**
**severe fibrosis/cirrhosis**

**ACTIVITY**
**0.85**
**A4**
**severe activity**

**STEATOSIS**
**0.80**
**S3**
**marked steatosis (≥67%)**

### INTERPRETATION

**S3-A4-F4**

Your result for the SAF score is **S3-A4-F4**. This score indicates that you have **marked steatosis (≥67%), severe activity and severe fibrosis/cirrhosis**. Consult your physician for further evaluation.

### BIOMARKER VALUES

 Age: **67 years**      Height: **5 ft, 5 in**      Weight: **232 lbs**      BMI: **\* 38.61**

Biomarker	Result	Unit	Biomarker	Result	Unit
Alpha2 Macroglobulin	2.41	g/L	ALT	167	IU/L
Haptoglobin	211	mg/dL	AST	104	IU/L
Apolipoprotein A1	144	mg/dL	Fasting Glucose	80	mg/dL
Total Bilirubin	0.24	mg/dL	Total Cholesterol	209	mg/dL
GGT	476	IU/L	Triglycerides	110	mg/dL

\* NOTE: The highlighted value is at the extremes of the acceptable range of biomarker values.

## WHAT LIVERFAST™ IS

**LIVERFAST™** is a noninvasive panel of tests combining patients' age, gender and body mass index with 10 biological blood markers correlated with liver conditions, to generate 3 different scores for estimating 3 lesions: fibrosis, activity and steatosis.

For each lesion, LIVERFAST™ evaluates a quantitative score (0.00 to 1.00) and its estimated grade or stage, similar to the liver biopsy classification. LIVERFAST™ graphs display the calculated score and the estimated grade or stage with a color code (from green that signifies normal or early condition to red, a severe condition).


LIVERFAST™ algorithm was built according to the latest MASLD histopathologic scoring system for categorizing liver lesions, the SAF score\*, that has two main advantages: to cover the entire spectrum of lesions (from S0A0F0 to S3A4F4) and to provide an activity score not biased by steatosis.

Liver damage (due to fibrosis, activity, steatosis) mainly due to metabolic syndrome risk factors (overweight, diabetes, excessive cholesterol, high blood pressure, etc.) or excessive alcohol intake can be improved by intensive lifestyle intervention (healthier lifestyle and/or reducing alcohol intake) and/or by drug treatment.

\*Bedossa P. and al. Hepatology 2012;56:1751-9


## HOW TO READ LIVERFAST™ RESULTS

**Fibrosis** is the progressive scarring of the liver leading to cirrhosis caused by the excessive accumulation of extracellular matrix, including collagen. Fibrosis could be reversible, more easily at early stages than late, and is mainly due to reaction from steatohepatitis (MASH)




Score	Stage	Interpretation
≥ 0.00 to < 0.07	F0	No fibrosis
≥ 0.07 to < 0.21	F1	Mild fibrosis
≥ 0.21 to < 0.52	F2	Significant fibrosis
≥ 0.52 to < 0.75	F3-F4	Advanced fibrosis

**Activity** related to MASLD is the inflammation and ballooning (severe hepatic cell injury) that occurs in the liver tissue which leads to steatohepatitis (MASH). MASH activity can be reversed.



Score	Grade	Interpretation
≥ 0.00 to < 0.15	A0	No activity
≥ 0.15 to < 0.24	A1	Mild activity
≥ 0.24 to < 0.42	A2	Moderate activity
≥ 0.42 to < 0.70	A3	Marked activity
≥ 0.70 to ≤ 1.00	A4	Severe activity

**Steatosis** is the accumulation of excessive fat (triglycerides) inside hepatocytes (liver cells). Steatosis is a reversible condition even at later stages.



Score	Grade	Interpretation
≥ 0.00 to < 0.19	S0	No steatosis (<5%)
≥ 0.19 to < 0.42	S1	Mild steatosis (5-33%)
≥ 0.42 to < 0.53	S2	Moderate steatosis (34-66%)
≥ 0.53 to ≤ 1.00	S3	Marked steatosis (≥ 67%)

NOTE: For readability, all score values shown are rounded to two significant digits – in boundary cases, where rounding suggests ambiguity, the stage rating should be considered as authoritative as the basis for interpretation. Graphs shown above are using sample data and are not based on the current patient's results.

## CONTACT US



615 Baronne Street,  
Suite 100, New Orleans,  
LA, 70113, USA

888-552-1603

321-256-6061

For clinical questions regarding the LIVERFAST report please contact the **Medical Affairs team at [medicalaffairs@fibronostics.com](mailto:medicalaffairs@fibronostics.com)**

For clinical questions regarding the biomarker values please contact the **Client Services team at [service@fibronostics.com](mailto:service@fibronostics.com)**